Navigation Links
Arena Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/9/2011

of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena'
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
5. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
6. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The ETC (Emerging Technology ... innovation centers, announced today that applications for AccelerateBaltimore™ ... 1st. “Do you have a big idea?,” asked ... to know about it. AccelerateBaltimore helps you and ... in just 13 weeks.” Interested game changers ...
(Date:11/26/2014)... CA (PRWEB) November 25, 2014 Silicon ... joins forces with RPM Alliance , provider of ... pharmaceutical companies. With the latest addition to its CRO ... free validated EDC system to India. , “We ... a robust and customizable EDC platform which is both ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le ... au salon Hi Europe 2014 (du 2 au ... Curcumine la plus biodisponible actuellement sur le ... des ingrédients approuvés par les règlements européens. ... dans la racine de curcuma ( Curcuma longa ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... in U.S. dollars, QUEBEC CITY, May 7 /PRNewswire-FirstCall/ ... a global biopharmaceutical company focused on,endocrinology and oncology, today ... March 31, 2008., First Quarter 2008 Highlights, ... trial of the Phase 3 program ...
... 1Q08 -- -- 1Q08 Net ... $0.12 versus 1Q07 Diluted EPS $.10 on 11.6 Million ... Additional Shares --, NEW ... company dedicated to,improving health through the development, manufacture and commercialization,of a broad range ...
... potential as a super material is blighted by the ... form of an unprepossessing pile of sooty black mess in ... University of Warwicks Department of Chemistry have found a way ... highly sensitive ready made electric circuit. , The research has ...
Cached Biology Technology:AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 2American Oriental Bioengineering Reports First Quarter 2008 Financial Results 3American Oriental Bioengineering Reports First Quarter 2008 Financial Results 4American Oriental Bioengineering Reports First Quarter 2008 Financial Results 5American Oriental Bioengineering Reports First Quarter 2008 Financial Results 6American Oriental Bioengineering Reports First Quarter 2008 Financial Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 8Nanotube production leaps from sooty mess in test tube to ready formed chemical microsensors 2
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... October 2011 - Genomatix is among the 41 partners ... Commission as a high impact project within its seventh ... sequencing data analysis and the development of an intuitive ... researchers within and outside the consortium. "To be ...
... that can strikingly reduce the number of risky diagnostic procedures ... to be introduced into clinical practice. The test can be ... who have been identified as being at high risk for ... study published online today in the journal Genetics in ...
... (UC Santa Barbara) Making waves as the ... a single layer of Carbon atoms has nonetheless ... be practical for innovative electronics applications. Researchers at UC ... quality graphene in a controlled manner that may pave ...
Cached Biology News:Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 2Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 3New method of growing high-quality graphene promising for next-gen technology 2New method of growing high-quality graphene promising for next-gen technology 3
...
Buckets for tube holder inserts...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... a microprocessor controlled, high speed filter ... exceptionally smooth operation make the Lambda ... fluorescence microscopy, ratio imaging, spectrophotometry, visual ... and accurate aperture positioning. The Lambda ...
Biology Products: